Fig 1.
Improving QoL through the use of STAT-ON™.
Fig 2.
The accompanying App enables configuring it at the beginning and generating the final report after the observation.
Table 1.
Number of PD patients by H&Y stage. Source: GlobalData. Parkinson’s disease: global drug forecast and market analysis to 2026 [82].
Table 2.
Average costs (€) per patient in 3 months in Spain in 2013.
Table 3.
Average costs (in €) in Sweden per H&Y. (EUR/SEK conversion rate in March 2025).
Table 4.
Average cost of advanced PD therapies per year in a 5-year study.
Fig 3.
Scenario 1. Moderate patient with STAT-ON™.
Fig 4.
Scenario 2. Advanced patient with STAT-ON™.
Table 5.
Average medication costs in five European regions (column 1), average costs of medication (column 2) and number of patients in Spain, Sweden, Germany, Italy and the UK (column 3).
Table 6.
Two rows presenting the number of patients not diagnosed with MF and as APD. The different columns present the estimation of non-correctly diagnosed patients per country, the number of these patients potentially detectable by STAT-ON™ and the number of these patients using STAT-ON™ when considering a market penetration of 20%.
Table 7.
Total savings in EUR in Health Systems in 5 countries considering the use of STAT-ON™ for the correct detection of symptoms.